Synchronicity Pharma

Synchronicity Pharma, founded in 2008 and based in San Jose, California, is a biotech company dedicated to developing transformative therapies that leverage circadian rhythm biology. Their core mission is to create innovative small molecule compounds that target the core-clock molecular machinery, aiming to modulate clock-regulated gene expression in humans. The company's primary focus is on pioneering cancer therapies that exploit cancer's dependence on circadian clock function.

Notable affiliated individuals include a world-leading team of scientists and researchers specializing in circadian biology and oncology. Synchronicity Pharma has attracted significant attention from investors due to its groundbreaking approach and successful development of the first-ever clinical-stage compound targeting circadian rhythms. The company's key achievements include demonstrating the safety and efficacy of their Cryptochrome modulator programs in clinical settings, positioning them as leaders in clock-based cancer therapies.